Q3 2024 Earnings Call Transcript November 7, 2024 Skye Bioscience, Inc. beats earnings expectations. Reported EPS is $-0.1, expectations were $-0.25. Operator: Ladies and gentlemen, thank you for ...

"The GLP1s are relatively new and are being rolled-out as scale. We have no idea what damage 20 years of drug-induced ...

Initiated Phase 2 STRIDES trial of azelaprag in combination with tirzepatide for obesityCompleted $238.3 million initial public offering and ...

Hanmi Pharm. Co., Ltd. has announced promising research results for its novel obesity treatment, HM17321. This groundbreaking drug not only augments fat loss but also significantly increases lean ...

CRB-913 demonstrated a wide dose response weight loss curve in DIO mice ranging from 5 mg/kg/day to 80 mg/kg/day with no plateauing effect and reaching a weight loss of 31% by day 19. Extending the ...

Skyrocketing demand for weight loss and diabetes drugs has forced Eli Lilly and Novo Nordisk, to invest billions to increase ...

LLY’s slashed revenue and earnings guidance for 2024 were a surprise, especially given substantial raises to its outlook ...

Eli Lilly reported third-quarter earnings and revenue below Wall Street expectations, reducing its full-year adjusted profit ...

Pfizer (PFE) offered up some more details on its weight loss drug pipeline on Tuesday during a call with investors after it ...

The study adds to evidence that GLP-1 receptor agonists (GLP-1RAs) like Semaglutide, which mimic the incretin hormone in the gut to stimulate insulin production in response to sugar overload, are ...

ALSO READ: Anti-ageing tips: Habits that are causing your age to skin and how to reverse the damage While the study was conducted on fruit flies, the researchers identified a similar incretin ...

The lawsuits target the online vendors Pivotal Peptide, which offers research-grade tirzepatide, and MangoRx, which markets a compounded version of the incretin therapy. Lilly is also suing the ...